Product Datasheet

Olutasidenib

Catalog No. **BP-01947** · CAS **1887014-12-1** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-02**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Isocitrate Dehydrogenase (IDH)	**Inflammation/Immunology; Cancer**

Molecular formula	$C_{18}H_{15}ClN_4O_2$
Molecular weight	**354.7900**

STRUCTURE



DESCRIPTION

Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively.

BIOLOGICAL ACTIVITY

In Vitro

Olutasidenib (FT-2102) potently inhibits 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), suggesting Olutasidenib (FT-2102) could be efficacious against most IDH1-R132 mutant-expressing tumors. Olutasidenib (FT-2102) is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 (> 20 μM) and IDH2 mutants (R172K and R140Q: both > 20 μM)[2].

In Vivo

Olutasidenib (FT-2102, three oral doses (12.5, 25, and 50 mg/kg) in 12-hour intervals) exhibits potent anti-tumor activity in HCT116-IDH1-R132H/+ xenograft bearing female BALB/c Nude mice[2].

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. JM Watts, et al. A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

[2]. Justin A. Caravella, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com